NewAmsterdam Pharma Company N.V.

NAMS · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$241,598-$176,937-$22,634-$41,785
Dep. & Amort.$113$49$9$5
Deferred Tax$0$0$0$0
Stock-Based Comp.$33,619$0$4,117$1,244
Change in WC-$32,674$5,866$10,373$4,470
Other Non-Cash$81,976$29,804$18,800$6,554
Operating Cash Flow-$158,564-$141,218$10,665-$29,512
Investing Activities
PP&E Inv.-$672-$24-$221-$24
Net Acquisitions$0$0$0$0
Inv. Purchases-$62,176$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow-$62,848-$24-$221-$24
Financing Activities
Debt Repay.$0$0$747$0
Stock Issued$645,507$8,912$396,952$84,704
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$14,000$0-$5,794$0
Financing Cash Flow$659,507$8,912$391,905$84,704
Forex Effect-$6,802$5,052$5,248-$4,683
Net Chg. in Cash$431,293-$127,278$407,597$50,485
Supplemental Information
Beg. Cash$340,450$467,728$60,131$9,646
End Cash$771,743$340,450$467,728$60,131
Free Cash Flow-$159,236-$141,242$10,444-$29,536
NewAmsterdam Pharma Company N.V. (NAMS) Financial Statements & Key Stats | AlphaPilot